Patents Assigned to FRED
  • COMPOSITIONS AND METHODS FOR DETECTING ALLOGENEIC MATTER IN A SUBJECT
    Publication number: 20210310068
    Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.
    Type: Application
    Filed: June 17, 2021
    Publication date: October 7, 2021
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: J. Lee Nelson, Nathalie C. Lambert, Vijayakrishna K. Gadi, Zhen Yan
  • Compositions, kits, and methods using interleukin-17C to promote neural growth and/or neural survival
    Patent number: 11135268
    Abstract: The present disclosure provides compositions, kits, and methods of promoting neural growth and/or neural survival using IL-17c. The compositions, kits, and methods can be used to promote neural growth and/or neural survival in a variety of conditions where such growth and survival is beneficial.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: October 5, 2021
    Assignees: Fred Hutchinson Cancer Research Center, University of Washington
    Inventors: Lawrence Corey, Jia Zhu, Tao Peng
  • METHODS AND COMPOSITIONS FOR ADOPTIVE T CELL THERAPY INCORPORATING INDUCED NOTCH SIGNALING
    Publication number: 20210292711
    Abstract: The disclosure provides in some aspect methods and compositions related to culturing and engineering T cells that maintain less differentiated state. The T cells are cultured in conditions that induce Notch signaling The resulting T cells exhibit maintenance of a less differentiated state for prolonged periods and have reduced susceptibility to exhaustion. Also provided are the cells produced by the methods, as well as related compositions and methods of use for adoptive therapy.
    Type: Application
    Filed: August 28, 2019
    Publication date: September 23, 2021
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Stanley R. Riddell, Irwin D. Bernstein, Margot J. Pont
  • Epstein Barr virus antibodies, vaccines, and uses of the same
    Patent number: 11116835
    Abstract: Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: September 14, 2021
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Andrew McGuire
  • COMPOSITIONS AND METHODS FOR EVADING BACTERIAL DEFENSE MECHANISMS
    Publication number: 20210277384
    Abstract: The present invention features modified polynucleotide sequences that mimic host cell DNA and methods of using such sequences for the genetic engineering of bacteria that are otherwise genetically intractable.
    Type: Application
    Filed: October 13, 2017
    Publication date: September 9, 2021
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: CHRISTOPHER D. JOHNSTON
  • BISPECIFIC AFFINITY REAGENT AND RELATED METHODS FOR PRETARGETED RADIOIMMUNOTHERAPY AGAINST CD45+ CELL
    Publication number: 20210269526
    Abstract: The disclosure is directed to bispecific affinity reagents, e.g., fusion proteins, that specifically bind to CD45 and radioactive ligands. The disclosure also addresses methods of use of the bispecific affinity reagents to specifically target cells with aberrant CD45 expression for therapy.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 2, 2021
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: Johnnie J. OROZCO
  • Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
    Patent number: 11098284
    Abstract: A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+ T lymphocytes prior to antigen stimulation, (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+ T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 24, 2021
    Assignee: The Fred Hutchinson Cancer Research Center
    Inventors: Cassian Yee, Yongqing Li
  • Cartilage-homing peptides
    Patent number: 11090358
    Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 17, 2021
    Assignees: FRED HUTCHINSON CANCER RESEARCH CENTER, BLAZE BIOSCIENCE, INC.
    Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
  • Circular tandem repeat proteins
    Patent number: 11078300
    Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: August 3, 2021
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Philip Bradley, Barry L. Stoddard
  • Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
    Patent number: 11066705
    Abstract: Methods of monitoring and measuring dynamic adaptive immune cell responses are provided. High-throughput sequencing of T cell receptor and immunoglobulin loci is used to characterize the breadth of an effector cell response to a stimulus, such as a vaccine or infection. Unique responding effector cell clones and abundance thereof can be determined. Additionally, methods for determining the contribution of responding effector cells to the immunological memory compartment are provided.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: July 20, 2021
    Assignees: Adaptive Biotechnologies Corporation, Fred Hutchinson Cancer Research Center
    Inventors: Harlan S. Robins, William Sumner DeWitt, III, Ryan O. Emerson
  • Method and compositions for cellular immunotherapy
    Patent number: 11065278
    Abstract: The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific CD8+ T cells in the presence of tumor-specific, subset specific genetically modified CD4+ T cells, wherein the CD4+ T cells confer and/or augment a CD8+ T cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific CD8+ T cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: July 20, 2021
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Stanley R. Riddell, Michael Hudecek
  • Compositions and methods for detecting allogeneic matter in a subject
    Patent number: 11060142
    Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: July 13, 2021
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: J. Lee Nelson, Nathalie C. Lambert, Vijayakrishna K. Gadi, Zhen Yan
  • SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
    Publication number: 20210198344
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 1, 2021
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • METHODS TO CREATE CHEMICALLY-INDUCED DIMERIZING PROTEIN SYSTEMS FOR REGULATION OF CELLULAR EVENTS
    Publication number: 20210198646
    Abstract: Methods to create chemically-induced dimerizing (CID) protein systems and uses thereof are described. The methods utilize antibody binding domain dimerizing proteins. The created systems can be used to regulate cellular events such as gene expression, receptor signaling and cell death to effectuate a variety of clinically relevant treatment outcomes.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 1, 2021
    Applicant: Fred Hutchinson Cancer Research Center
    Inventor: Rupesh Amin
  • METHODS FOR DETERMINING THE PRESENCE OR RISK OF DEVELOPING FACIOSCAPULOHUMERAL DYSTROPHY (FSHD)
    Publication number: 20210198739
    Abstract: In one aspect, the invention provides a method of screening a human subject to determine if said subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD), said method comprising: (a) providing a biological sample comprising genomic DNA from the subject; and (b) analyzing the portion of the genomic DNA in the sample corresponding to the distal D4Z4-pLAM region on chromosome 4 and determining the presence or absence of a polymorphism resulting in a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene.
    Type: Application
    Filed: December 7, 2020
    Publication date: July 1, 2021
    Applicants: Fred Hutchinson Cancer Research Center, University of Rochester, Leiden University Medical Center
    Inventors: Silvere M. van der Maarel, Stephen J. Tapscott, Rabi Tawil, Richard J.L.F. Lemmers, Linda Geng, Laura Snider
  • Tagged chimeric effector molecules and receptors thereof
    Patent number: 11046766
    Abstract: The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the recombinant host cell can be identified, isolated, sorted, induced to proliferate, tracked or eliminated. For example, a T cell may be recombinantly modified for use in adoptive immunotherapy.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: June 29, 2021
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Stanley R. Riddell, Lingfeng Liu
  • Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
    Patent number: 11047008
    Abstract: Methods are provided for predicting a subject's infection status using high-throughput T cell receptor sequencing to match the subject's TCR repertoire to a known set of disease-associated T cell receptor sequences. The methods of the present invention may be used to predict the status of several infectious agents in a single sample from a subject. Methods are also provided for predicting a subject's HLA status using high-throughput immune receptor sequencing.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: June 29, 2021
    Assignees: Adaptive Biotechnologies Corporation, Fred Hutchinson Cancer Research Center
    Inventors: Ryan O. Emerson, Harlan S. Robins, Mark Rieder, William Dewitt, III, Christopher Carlson
  • Method of identifying human compatible T cell receptors specific for an antigenic target
    Patent number: 11041202
    Abstract: Methods are provided for identifying T cell receptors that specifically bind a particular antigenic target and can be used as therapeutics against disease.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: June 22, 2021
    Assignees: Adaptive Biotechnologies Corporation, Fred Hutchinson Cancer Research Center
    Inventors: Harlan S. Robins, Aude Georgiana Chapuis, Thomas M. Schmitt, Philip Greenberg, Anna Sherwood
  • High affinity MAGE-A1-specific TCRs and uses thereof
    Patent number: 11034748
    Abstract: The present disclosure provides TCRs with high or enhanced affinity against various tumor associated antigens (including human MAGE-A1 epitopes), T cells expressing such high affinity antigen-specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress one or more of these antigens, such as in cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: June 15, 2021
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Aude Chapuis, Thomas Schmitt, Megan McAfee
  • GENOMIC SAFE HARBORS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND ENGINEERED NANOPARTICLES TO PROVIDE TARGETED GENETIC THERAPIES
    Publication number: 20210171983
    Abstract: Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.
    Type: Application
    Filed: June 5, 2018
    Publication date: June 10, 2021
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Jennifer E. Adair, Reza Shahbazi